Metabolic imaging of hyperpolarized [1-13C]pyruvate was performed in four patients with pancreatic ductal adenocarcinoma prior to chemotherapy. Compared to the normal appearing pancreas, higher lactate/pyruvate and lower alanine/pyruvate ratios were seen in the primary tumors. The alanine/lactate ratio, which reflects the relative enzymatic activity and metabolite pool sizes, was reduced 2- to 20-fold in the tumors and provided improved contrast between tumor and normal appearing pancreas over either the lactate/pyruvate or alanine/pyruvate ratio. These results indicate the potential for HP 13C MRI to be a novel tool to stage disease and assess treatment response in pancreatic cancer patients
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords